Calcium-channel blockers in the treatment of migraine.
According to classic theory, a migraine attack is initiated by cerebrovascular spasm followed by extracranial vasodilatation. Results of recent studies support this theory and suggest that cerebral blood flow during the initial phase of migraine symptoms is, in fact, decreased and this decrease probably leads to ischemia and hypoxia. Cellular hypoxia, in turn, can cause an increase in the flow of calcium from the extracellular fluid to the intracellular space, resulting in calcium overload and cellular dysfunction. Because calcium-channel blockers selectively inhibit the intracellular influx of calcium ions, investigators have begun evaluating the efficacy of these agents for migraine prophylaxis. Nimodipine, a calcium-channel blocker that exhibits selective effects on cerebral vessels, seems to offer protection against the cerebral ischemia and hypoxia presumed to be operative during migraine attacks. In a double-blind, placebo-controlled study, nimodipine decreased the frequency and duration of migraine attacks by at least half in 69% of patients treated with this agent. Comparable reductions in migraine frequency and duration were attained in 58, 51, 41 and 52% of patients treated with methysergide maleate, pizotifen, clonidine hydrochloride and propranolol, respectively. The piperazine derivative flunarizine also has calcium-channel blocking properties. This agent prevents vasospasm in cerebral arteries and protects against cerebral hypoxia. Results of double-blind studies of migraine prophylaxis with flunarizine demonstrate the beneficial effects of this agent, particularly in younger patients. Flunarizine proved to be superior to pizotifen in decreasing the severity of migraine attacks and comparable to pizotifen in decreasing their frequency.(ABSTRACT TRUNCATED AT 250 WORDS)
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002936:Cinnarizine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004311:Double-Blind Method; D005444:Flunarizine; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology; D008881:Migraine Disorders / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D009539:Nicotinic Acids / Q000627:therapeutic use; D009553:Nimodipine; D014665:Vasodilator Agents / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D009539:Nicotinic Acids; D014665:Vasodilator Agents; D002936:Cinnarizine; D009553:Nimodipine; D005444:Flunarizine